| Objective:In this study,The clinical efficacy of Sacubitril/valsartan and Perindopril in patients with chronic heart failure were compared by observing the changes of echocardiographic indexs,N-terminal pro-brainnatriuretic peptide(NT-proBNP),renal function,serum potassium,the score of kansas city cardiomyopathy questionnaire(KCCQ)and other corresponding indicators through 3 months and 6 months treatment.Meanwhile,the safety of the two drugs were compared through the recently major adverse cardiovascular events and drug-related adverse reactions of the patients.Methods:A total of 155 patients diagnosed chronic heart failure in inpatient or outpatient deparent of cardiovascular medicine of the Affiliated Hospital of North Sichuan Medical College from June 2018 to June 2019 who were selected for the study.The patients in this study were divided into Sacubitril/valsartan group(group A)and Perindopril group(group B)by random number table method,all the patients of the two groups were given conventional anti-HF drugs treatment,and the patients of Sacubitril/valsartan group were treated with Sacubitril/valsartan and conventional drugs such as?-blockers,aldosterone antagonist,digitalis,diuretics,vasodilators.Perindopril and the same conventional anti-HF drugs were treated in Perindopril group.We collected the general clinical data from these patients,including gender,age,BMI,smoking history,past medical history,comorbidities and other medications,then we observed the changes of echocardiographic indexs,NT-proBNP,renal function,serum potassium,the score of KCCQ after three months and six months continuously treatment.The drug-related adverse reactions and the major clinical adverse cardiovascular events of the patients were also recorded.The all results were analyzed by SPSS 25.0 software.Results:1.There was no statistically significant difference in gender,age,BMI,smoking history,anamnesis,primary diseases,the other kinds of anti-HF tablets,classification of cardiac function(NYHA)and the type of heart failure between the two groups(P>0.05),The number of the patients who were given tablets by outpatient department in group B was greater than group A,and the difference was statistically significant(P<0.05).2.The left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDd),left ventricular diameter(LA)and Left ventricular mass index(LVMI)of the two groups were no statistically significant before treatment(P>0.05),LVEF was higher than before both two groups after 3 months and 6 months of treatment,and the difference was statistically significant(P<0.05),meanwhile after 6 months of treatment in heart failure with reduced ejection fraction(HFrEF)and heart failure with med-range ejection fraction(HFmrHF)subgroups,LVEF in group A was higher than that in group B,and the difference between the two groups was statistically significant(P<0.05),the difference wasn't statistically significant in other A,B groups(P>0.05).LVEDd,LA and LVMI of the HFrHF,HFmrHF and heart failure with preserved ejection fraction(HFpHF)subgroups were all decreased compared with those before treatment,whose difference was statistically significant(P<0.05),but the difference of A,B groups was no statistically significant(P>0.05).3.There was no statistically significant difference in NT-proBNP between the two groups before treatment(P>0.05),NT-proBNP of two groups were all decreased compared with those before treatment,whose difference was statistically significant(P<0.05),NT-proBNP in group A was lower than that in group B after3 and 6 months of treatment,and the difference between the two groups was statistically significant(P<0.05).4.The serum creatinine,blood urea nitrogen(BUN),estimated glomerular filtration ratee(eGFR),uric acid,serum potassium were no statistically significant difference before treatment(P>0.05),the differences were no statistically significant after 3 and 6 months of treatment(P>0.05).The Cystatin C(CysC)was decreased compared with those before treatment,which difference was statistically significant(P<0.05),but the difference of A,B groups wasn't statistically significant(P>0.05).5.The score of KCCQ was no significant difference before treatment of two groups(P>0.05),the score of KCCQ was all higher than those before treatment,which difference was statistically significant(P<0.05),meanwhile the score of KCCQ in group A was higher than that in group B after 6 months of treatment,and the difference between the A,B groups was statistically significant(P<0.05).6.The number of dry cough cases in group A was lower than that in group B,and the difference between the two groups was statistically significant(P<0.05),the other and all incidence of drug-related adverse reactions were no statistical difference(P>0.05).7.There was no statistically significant difference in the clinical adverse cardiovascular events between the two groups(P>0.05).8.The initial dose of Sacubitril/Valsartan in goup A was 67.26±23.92mg per day,176.78±64.68mg per day of Sacubitril/Valsartan in group A after three months,196.42±60.51mg per day of Sacubitril/Valsartan were finally given in group A after 6 months,the initial dose of Perindopril in goup B was 4.34±1.12mg per day,5.97±2.01mg per day of Perindopril in group B after 3 months,the final dose of Perindopril in group B was 6.59±1.92mg per day after 6 months.Conclusion:1.Both Sacubitril/Valsartan and Perindopril can improve left ventricular remodeling in different types of chronic patients,The Sacubitril/Valsartan is better than Perindopril at improving cardiac functionin in HFrEF and HFmrEF subgroups though 6 months of treatment.2.Sacubitril/Valsartan reduce the NT-proBNP and improve the quality of life of patients more effectively than perindopril.3.The incidence of the drug-related adverse reactions and the clinical adverse cardiovascular events of the Sacubitril/Valsartan and Perindopril was low,which means the safety of the two drugs is great. |
PDF Full Text Request